Skip to main content

Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel [Tecartus®])

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion due to NICE appraisal TA677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma

Medicine details

Medicine name Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel [Tecartus®])
Formulation Solution for infusion
Reference number 4795
Indication

Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor

 

Company Gilead Sciences Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
Date of issue 21/01/2021
NICE guidance

TA677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma

Commercial arrangement